若生智能
Drug Database
PR

prednisolone farnesil (Farnezone / Farnesone / Farnerate)

✓ Approved

SK · NR3C1 · 小分子

什么是 prednisolone farnesil？

prednisolone farnesil 是一种小分子，由SK研发。该药已获批，用于治疗相关适应症，给药途径：Topical。

药物档案

商品名Farnezone, Farnesone, Farnerate
公司SK
药物类别小分子
分子靶点NR3C1
给药途径Topical
状态Approved
来源： ClinicalTrials.gov, SK

作用机制

分子靶点

prednisolone farnesil 作用于 1 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

prednisolone farnesil 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved

相关研究文献

PubMedJournal for immunotherapy of cancer2026-06-13

Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study.

Wein Lisa L, Ertl Carolin C, Ruf Theresa T, Morak Monika M et al.

Immune checkpoint inhibitor-induced immune-related adverse events (irAEs) can be steroid-refractory (sr) or steroid-dependent (sd), requiring second-line therapy. Evidence guiding optimal management of sr/sd-irAEs while preserving antitumor efficacy is scarce. This study compared extracorporeal photopheresis (ECP) with systemic immunosuppressants (IS) for treatment of sr/sd-irAEs. This prospective two-arm study included 46 patients (23 ECP, 23 IS) with 12 distinct types of irAEs across 6 tumor entities, all classified as steroid-refractory or steroid-dependent. Toxicities affected the gastrointestinal tract, skin, lung, musculoskeletal system, and serosal membranes, with up to seven prior irAE treatment lines. Patients received six cycles of ECP or investigator's choice IS over 12 weeks. Longitudinal assessments included clinical irAE outcomes, quality of life (QoL), and tumor response. ECP was more frequently used in patients with multi-toxicity (39% vs 9%; p=0.02) and multi-resistance to prior second-line immunosuppression (39% vs 17%; p=0.19). At week 12, ECP showed a lower cumulative corticosteroid exposure (395 mg vs 1,260 mg prednisolone equivalent; p=0.03), significantly improved QoL (p=0.01), and a numerically higher irAE response rate without statistical significance compared with IS (94% vs 81%; p=0.85). In advanced cutaneous melanoma, ECP was associated with superior overall survival (15 vs 10 months; p=0.02), and longer progression-free survival (9 vs 3 months; p=0.01). No significant safety concerns were observed with ECP; one fatality in the IS group was infection-related. ECP demonstrated clinical outcomes comparable to IS in sr/sd-irAEs, with significantly lower cumulative corticosteroid exposure and improved QoL. Furthermore, ECP was associated with a favorable safety profile and showed no evidence of compromised antitumor activity. A multicenter trial is planned for further investigation. NCT05700565.

PMID 42285609
阅读全文 →
PubMedJournal of medical case reports2026-06-13

Paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features: a diagnostic challenge-a case report.

Malangwa Godfrey G, Mushengezi Brighton B, Lyatuu Limika L, Mwapule Luth L et al.

Paraneoplastic neurologic syndromes (PNS) are rare immune-mediated disorders that may precede the diagnosis of an underlying malignancy, including non-small cell lung cancer (NSCLC). Tumor heterogeneity in NSCLC, particularly in rare subtypes such as adenosquamous carcinoma, may result in variable histologic findings across different biopsy sites, posing significant diagnostic challenges. We report a case of a 45-year-old Tanzanian male, a never-smoker, who presented with progressive neurologic symptoms, including ageusia, dystonia, paresthesia, and ataxia, without respiratory complaints. Brain Magnetic resonance imaging (MRI) demonstrated diffuse cerebral microhemorrhages, and extensive autoimmune and neuronal antibody testing was negative. He received intravenous methylprednisolone followed by an oral prednisolone taper with transient stabilization. Positron emission tomography-computed tomography (PET-CT) revealed an ill-defined FDG-avid right lower lobe lesion and vertebral metastases. Biopsy of a T10 vertebral lesion confirmed metastatic lung adenocarcinoma (TTF-1 positive), and the disease was staged as stage IV (cTxNxM1b). The patient was treated with carboplatin and pemetrexed, with partial neurologic improvement. During disease progression, repeat bronchoscopy biopsy revealed tumor cells with squamous features (p63 positive, patchy TTF-1 expression), raising the possibility of mixed histology (adenosquamous). However, histologic transformation cannot be completely excluded due to a lack of molecular analysis. His condition deteriorated rapidly, and he died from complications of advanced metastatic disease with progressive neurologic involvement. This case highlights the diagnostic challenges of antibody-negative paraneoplastic neurologic syndromes. The study underscores the important role of PET-CT in identifying occult malignancy and the role of repeat biopsy in progressive disease. Discordant histologic findings should be interpreted cautiously, as they may reflect tumor heterogeneity or possible adenosquamous carcinoma rather than true histologic evolution. Limited molecular testing, and sampling constraints remain important challenges, particularly in resource-limited settings.

PMID 42286636
阅读全文 →
PubMedBMJ open2026-06-12

Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency: a study protocol for a multicentre, randomised, double-blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis on low-dose prednisolone treatment (the RESCUE study).

Borresen Stina Willemoes SW, Hansen Simon Bøggild SB, Al-Jorani Hajir H, Tei Randi R et al.

Patients on low-dose prednisolone may develop adrenal insufficiency causing reduced health-related quality of life (HRQoL) and increased risk of adrenal crisis. This study examines whether supplemental hydrocortisone during mild to moderate stress improves HRQoL in patients with polymyalgia rheumatica/giant cell arteritis (PMR/GCA) with adrenal insufficiency on low-dose prednisolone. A multicentre, randomised, double-blinded, placebo-controlled, clinical trial including patients with PMR/GCA receiving ongoing prednisolone ≤5 mg/day. Eligible patients undergo an adrenocorticotropic hormone (ACTH) test, and 250 patients with a stimulated cortisol<420 nmol/L (biochemical adrenal insufficiency) are randomised 1:1 to supplemental hydrocortisone or placebo during mild to moderate stress ('sick-days') for 6 months or until daily prednisolone is stopped. The goal is 200 patients completing ≥3 months intervention period. Patients continue prednisolone tapering according to PMR/GCA guidelines. In the event of severe stress (risk of adrenal crisis), patients receive open-label hydrocortisone treatment. 95 patients with stimulated cortisol ≥420 nmol/L serve as control group. The primary outcome is HRQoL measured as fatigue using ecological momentary assessments (EMA) of the General Fatigue scale from the Multidimensional Fatigue Inventory-20, five times daily in situations of stress ('sick-days'). EMA will be administered via a smartphone application 'EMA live'. Differences in mean fatigue scores during sick-days between hydrocortisone and placebo will be analysed using mixed models for repeated measures. Secondary outcomes include daily smartphone-based symptom reporting, additional HRQoL questionnaires, adrenal crises, adverse effects from glucocorticoid excess, serial ACTH tests and biomarkers of adrenal insufficiency. The study is approved by the Ethics Committee of the Capital Region of Denmark and the Danish Medicines Agency. Recruitment began June 2022. The last patient's last visit is expected in 2026. Results will be disseminated via peer-reviewed publication and conference presentations. EudraCT:2021-002528-18, CTIS:2024-518272-30-00, NCT05435781.

PMID 42276802
阅读全文 →
PubMedJACC. Case reports2026-06-12

Regression of Left Main Coronary Stenosis During Long-Term Tocilizumab Therapy in Takayasu Arteritis.

Arita Yoh Y, Ogasawara Nobuyuki N

We report a 29-year-old woman with Takayasu arteritis and critical left main coronary artery stenosis treated with prednisolone, tocilizumab, and coronary artery bypass grafting. Serial computed tomography angiography over 6 years demonstrated delayed yet marked regression of coronary stenosis despite minimal early change. Improvement occurred during a period of sustained inflammatory control and careful glucocorticoid tapering. No cardiovascular events or relapse occurred, and graft patency was preserved. This case suggests that prolonged suppression of vascular inflammation may be associated with delayed improvement in coronary stenosis in selected patients with Takayasu arteritis. Sustained inflammatory control with long-term tocilizumab therapy and carefully tapered glucocorticoids may be associated with delayed improvement of coronary artery stenosis in Takayasu arteritis. Monitoring inflammatory biomarkers, including interleukin-6 trends when conventional markers are suppressed, may support individualized glucocorticoid tapering strategies.

PMID 42283689
阅读全文 →
PubMedRMD open2026-06-12

[68Ga]Ga-DOTA-Siglec-9 PET/CT in newly diagnosed giant cell arteritis: an inflammation-specific, treatment-responsive molecular imaging biomarker.

Petzinna Simon M SM, Küppers Jim J, Schemmer Benedikt B, Jamin Raul N RN et al.

Assessing disease activity in giant cell arteritis (GCA) remains challenging, as existing clinical, laboratory and imaging biomarkers lack specificity. This proof-of-concept study explored the diagnostic potential of vascular adhesion protein-1 (VAP-1) targeting [68Ga]Ga-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) DOTA-sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) positron emission tomography-CT (PET/CT) as an inflammation-specific molecular imaging biomarker in newly diagnosed and relapsing GCA. Patients with newly diagnosed GCA underwent [68Ga]Ga-DOTA-Siglec-9 PET/CT and vascular ultrasound. Tracer uptake (SUVmean/SUVmax) was quantified in aortic, supra-aortic and extravascular (shoulder/hip) regions and compared with relapsing patients. Levels of soluble VAP-1 (sVAP-1) and matrix metalloproteinase (MMP)2/MMP3/MMP9 were measured in patients and controls as potential biomarkers related to vascular inflammation. Eight patients with newly diagnosed GCA were compared with eight relapsing patients, alongside eight controls. Imaging revealed a positive association between ultrasound-assessed subclavian artery intima-media thickness and tracer uptake (r=0.67, p=0.035). Prednisolone exposure was inversely associated with vascular uptake across various vascular regions, with SUVmean showing a stronger overall negative association than SUVmax (SUVmean r=-0.51, p=0.043; SUVmax r=-0.62, p=0.010). Levels of sVAP-1 were reduced in newly diagnosed GCA compared with relapsing patients (p=0.0145) and controls (p=0.0446), and inversely associated with MMP2 (r=-0.56, p=0.037) and MMP9 (r=-0.47, p=0.089). Notably, MMP2 and MMP3 were negatively associated with vascular uptake (eg, aortic arch: r=-0.59, p=0.027). This first-in-human study demonstrates that [68Ga]Ga-DOTA-Siglec-9 PET/CT detects vascular inflammation in GCA and shows attenuation with prednisolone exposure. Reduced sVAP-1 levels and inverse associations between MMP2/MMP3 and tracer uptake support a functional VAP-1/MMP axis underlying the imaging signal. Our findings further position [68Ga]Ga-DOTA-Siglec-9 PET/CT as a promising potential molecular imaging biomarker in GCA.

PMID 42276732
阅读全文 →
PubMedInternal medicine (Tokyo, Japan)2026-06-11

A Case of Adult-Onset Still's Disease Diagnosed Following Treatment for Scrub Typhus.

Tani Asuka A, Matsuo Haruna H, Fujikawa Keita K, Umetsu Ayaka A et al.

A 28-year-old woman, previously diagnosed with seronegative rheumatoid arthritis, was admitted with fever, vomiting, and diarrhea. She developed septic shock with disseminated intravascular coagulation and was treated with antibiotics, noradrenaline, prednisolone, and thrombomodulin. On day 3, a rash appeared, and polymerase chain reaction detected Orientia tsutsugamushi deoxyribonucleic acid, thus confirming the diagnosis of scrub typhus. Her symptoms resolved after minocycline treatment. After tapering the prednisolone, fever, rash, and arthralgia recurred. Laboratory tests revealed elevated ferritin and interleukin-18 levels. After excluding other causes, adult-onset Still's disease (AOSD) was diagnosed in this patient. The patient exhibited a rapid improvement following tocilizumab treatment. Scrub typhus and AOSD share overlapping features that complicate diagnosis.

PMID 42270388
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多prednisolone farnesil